Download PDF
Z Gastroenterol 2001; 39(2): 181-190
DOI: 10.1055/s-2001-11483
Übersichten
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Palliative Therapie des Pankreasadenokarzinoms

J.-M Löhr
  • Medizinische Klinik IV, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg
Further Information

Publication History

3.3.2000

25.4.2000

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die palliative Therapie des Pankreasadenokarzinoms besteht aus Basistherapie (best supportive care/BSC), zu der insbesondere die Schmerz- und Ernährungstherapie gehört, sowie in einer palliativen antineoplastischen Therapie. Ergänzt wird dies durch interventionell-therapeutische endoskopische Maßnahmen, die den Gallefluss wiederherstellen oder die Kontinuität des oberen Darmlumens durch die Einlage von Endoprothesen wahren. Die Schmerztherapie wird heute standardmäßig nach dem WHO-Schema durchgeführt, während die Ernährungstherapie häufig vernachlässigt wird. Für die palliative Chemotherapie empfiehlt sich entweder Gemcitabine oder 5-FU. Kombinationen mit anderen Zytostatika oder Bestrahlung befinden sich derzeit - im Rahmen von Studien - im Erprobungsstadium. Eine Reihe von rationalen Therapiekonzepten hat sehr gute Ergebnisse in tierexperimentellen und präklinischen Experimenten gezeigt, jedoch haben nur wenige Ansätze den Weg in frühe klinische Studien (Phase I/II) gefunden.

Palliative therapy of pancreatic carcinoma

The palliative therapy of pancreatic carcinoma consists of best supportive care (BSC) including nutritional and pain therapy, and antineoplastic remedies. This is complemented by interventional endoscopy aiming to treat obstructive jaundice and/or gastric or duodenal obstruction by implantation of endoprostheses. Pain therapy is standardized for the most part according to the WHO guidelines; nutrition of the cancer patient, however, is sometimes disregarded. For palliative chemotherapy, 5-fluorouracil and gemcitabine can be recommended. Combinations thereof with other cytostatic drugs or radiation are subject to ongoing studies. A variety of novel therapeutic concepts, e. g. immunomodulation or suicide gene therapy, have demonstrated good effects in animal studies. Unfortunately, very few of these have entered clinical studies (phase I and phase II). This will be the focus of future research in this field.

Schlüsselwörter

Pankreaskarzinom - Therapie - Chemotherapie - Gentherapie

Key words

Pancreatic Carcinoma - Therapy - Review - Chemotherapy - Gene Therapy

Literatur

  • 1 Gudjonsson B. Carcinoma of the pancreas: Critical analysis of costs, results of resections, and the need for standardization.  J Am Coll Surg. 1995;  181 483-503
    Google Scholar
  • 2 Huguier M, Mason N P. Treatment of cancer of the exocrine pancreas.  Am J Surg. 1999;  177 257-265
    Google Scholar
  • 3 Büchler M, Wagner M. Chirurgie des Pankreaskarzinoms. Schmiegel W, Herfarth C, Fischbach WFUR, editors Diagnostisches und therapeutisches Management gastrointestinaler Tumoren. 5. Postgraduiertenkurs der DGVS Konstanz, Byk Gulden/DGVS; 1998
    Google Scholar
  • 4 Henne-Bruns D, Vogel I, Lüttges J, Klöppel G, Kremer B. Ductal adenocarcinoma of the pancreas head: Survival after regional versus extended lumphadenectomy.  Hepatogastroenterology. 1998;  45 855-866
    Google Scholar
  • 5 Lillemoe K D, Cameron J L, Yeo C J. et al . Pancreaticoduodenectomy: does it have a role in the palliation of pancreatic cancer?.  Ann Surg. 1996;  223 718-728
    Google Scholar
  • 6 Rosenberg L. Treatment of pancreatic cancer.  Int J Pancreatol. 1997;  22 81-93
    Google Scholar
  • 7 Ahlgren J D. Chemotherapy for pancreatic carcinoma.  Cancer. 1996;  78 654-663
    Google Scholar
  • 8 Böhmig M, Wiedenmann B, Rosewicz S. Therapie des Pankreasadenokarzinoms.  Med Klin. 1999;  94 614-625
    Google Scholar
  • 9 Hedberg M, Borgström A, Genell S, Janzon L. Survival following pancreatic carcinoma: A follow-up study of all cases recorded in Malmö, Sweden, 1977-1991.  Br J Surg. 1998;  85 1641-1644
    Google Scholar
  • 10 Rosewicz S, Wiedenmann B. Pancreatic carcinoma.  Lancet. 1997;  349 485-489
    Google Scholar
  • 11 Warshaw A L, Castillo C F. Pancreatic carcinoma.  N Engl J Med. 1992;  326 455-465
    Google Scholar
  • 12 Wright J C, Weinstein M C. Gains in life expectancy from medical interventions - standardizing data on outcomes.  N Engl J Med. 1998;  339 380-386
    Google Scholar
  • 13 Slevin M L, Stubbs L, Plant H J. et al . Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public.  BMJ. 1990;  300 1458-1460
    Google Scholar
  • 14 Wenger F A, Jacobi C A, Haubold K, Zieren H U, Müller J M. Gastrointestinale Lebensqualität nach Duodenopankreatektomie beim Pankreaskarzinom.  Chirurg. 1999;  70 1454-1459 Abstract
    Google Scholar
  • 15 Fitzsimmons D, Johnson C D, George S. et al . Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnnaire, the QLQ-C30 in patients with pancreatic cancer.  Eur J Cancer. 1999;  35 939-941
    Google Scholar
  • 16 Fitzsimmons D, Johnson C D. Quality of life after treatment of pancreatic cancer.  Langenbecks Arch Surg. 1998;  383 145-151
    Google Scholar
  • 17 Passik S D, Breitbart W S. Depression in patients with pancreatic carcinoma.  Cancer. 1996;  78 (Suppl. 3) 615-626
    Google Scholar
  • 18 Surbone A, Zwitter M. Communication with the cancer patient. Information & truth New York; New York Academy of Sciences 1997
    Google Scholar
  • 19 Fitzsimmons D, George S, Payne S, Johnson C D. Differences in perception of quality of life issues between health professionals and patients with pancreatic cancer.  Psychooncology. 1999;  8 135-143
    Google Scholar
  • 20 Caraceni A G, Portenoy R K. Pain management in patients with pancreatic carcinoma.  Cancer. 1996;  78 (Suppl. 3) 639-653
    Google Scholar
  • 21 World Health Organization (WHO) .Cancer pain relief and palliative care. WHO; 2nd ed. Geneva 1990
    Google Scholar
  • 22 Grond S, Zech D, Lehmann K A. et al . Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region.  Pain. 1997;  69 191-198
    Google Scholar
  • 23 Wigmore S J, Plester C E, Richardson R A, Fearon K CH. Changes in nutritional status associated with unresectable pancreatic cancer.  Br J Cancer. 1997;  75 106-109
    Google Scholar
  • 24 Downer S, Joel S, Albright A. et al . A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.  Br J Cancer. 1993;  67 1102-1105
    Google Scholar
  • 25 Greenway B A. Effect of flutamide on survival in patients with pancreatic cancer: Results of a prospective, randomized, double blind, placebo controlled trial.  BMJ. 1998;  316 1935-1938
    Google Scholar
  • 26 Braganza J M, Howat H T. Cancer of the pancreas.  In: Howat HT, editor. The exocrine pancreas. London: W.B. Saunders Ltd. 1972;  219-237
    Google Scholar
  • 27 Friess H, Bohm J, Ebert M, Büchler M. Enzyme treatment after gastrointestinal surgery.  Digestion. 1993;  54 (Suppl. 2) 48-53
    Google Scholar
  • 28 Bruno M J, Haverkort E B, Tijssen G P, Tytgat G N, van Leeuwen D J. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region.  Gut. 1998;  42 92-96
    Google Scholar
  • 29 Gullo L, Pezzilli R, Morselli-Labate A M. Diabetes and the risk of pancreatic cancer. Italian pancreatic cancer study group.  N Engl J Med. 1994;  331 81-84
    Google Scholar
  • 30 Andreyev H J, Norman A R, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?.  Eur J Cancer. 1998;  34 503-509
    Google Scholar
  • 31 Diwok K, Gülzow M, Moldenhauer W, Putzke H P, Herzog K H. Tumoren des Pankreas. Gülzow M Erkrankungen des exkretorischen Pankreas Jena; Gustav Fischer Verlag 1975 1 ed: 209-242
    Google Scholar
  • 32 Passik S D, Roth A J. Anxiety sympoms and panic attacks preceding pancreatic cancer diagnosis.  Psychooncology. 1999;  8 268-272
    Google Scholar
  • 33 Gorter R W. Cancer cachexia and cannabinoids.  Forsch Komplementarmed. 1999;  6 (Suppl. S3) 21-22
    Google Scholar
  • 34 Clinical P racice and Practive Economics Committee. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma.  Gastroenterology. 1999;  117 1464-1484
    Google Scholar
  • 35 Rosewicz S, Böhming M. Palliative Chemotherapie des Pankreaskarzinoms. Schmiegel W, Herfarth C, Fischbach W, Fölsch UR Diagnostisches und therapeutisches Management gastrointestinaler Tumoren. 5. Postgraduiertenkurs der DGVS Konstanz, Byk Gulden/DGVS; 1998
    Google Scholar
  • 36 Schmoll H J, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil?.  Semin Oncol. 1999;  26 589-605
    Google Scholar
  • 37 Carter S K, Comis L. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.  Cancer Treat Rev. 1975;  2 193-214
    Google Scholar
  • 38 Crown J, Casper E S, Botet J, Murray P, Kelsen D P. Lack of efficacy of high-dose leucovorin and fluoruracil in patients with advanced pancreatic adenocarcinoma.  J Clin Oncol. 1991;  9 1682-1686
    Google Scholar
  • 39 Nose H, Okada S, Okusaka T. et al . 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: A japanese cooperative study.  Hepatogastroenterology. 1999;  46 3244-3248
    Google Scholar
  • 40 Lutz M P, Königer M, Muche R. et al . A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.  Z Gastroenterol. 1999;  37 993-997
    Google Scholar
  • 41 Cerny T, Martinelli G, Goldhirsch A. et al . Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: A phase II study.  J Cancer Res Clin Oncol. 1991;  117 S135-S138 (Suppl IV)
    Google Scholar
  • 42 Maiello E, Gebbia V, Giuliani F. et al . A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma.  Clin Ther. 1998;  149 351-355
    Google Scholar
  • 43 Tsavaris N, Tentas K, Tzivras M. et al . Combined epirubicin, 5-fluorouraciland folinic acid vs no treatment for patients with advanced pancreatic cancer: A prospective comparative study.  J Chemother. 1998;  10 331-337
    Google Scholar
  • 44 Wadler S, Damle S, Haynes H. et al . Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alpha-2a in patients with refractory malignancies of the gastrointestinal tract.  J Clin Oncol. 1999;  17 1771-1778
    Google Scholar
  • 45 Whitehead R P, Jacobson J, Brown T D. et al . Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest oncology group study.  J Clin Oncol. 1997;  15 2414-2419
    Google Scholar
  • 46 Burris H A, Moore M J, Andersen J. et al . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial.  J Clin Oncol. 1997;  15 2403-2413
    Google Scholar
  • 47 Carmichael J. Clinical response benefit in patients with advanced pancreatic cancer.  Digestion. 1997;  58 503-507
    Google Scholar
  • 48 Storniolo A M, Enas N H, Brown C A. et al . An investigational new drug treatment program for patients with gemcitabine.  Cancer. 1999;  85 1261-1268
    Google Scholar
  • 49 Peters H D, Blatter J, Ermisch S. Gemcitabin. Pharmakologisches Profil und klinische Anwendung.  Onkologe. 1995;  1 367-382
    Google Scholar
  • 50 Noble S, Goa K L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.  Drugs. 1997;  54 447-472
    Google Scholar
  • 51 Iliger H J, Bornmann L, Herdich K. Arzneimittelinteraktionen bei der Therapie maligner Erkrankungen. München; W. Zuckschwerdt Verlag 1995
    Google Scholar
  • 52 Cao Z, Harris N, Kozielski A. et al . Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.  J Med Chem. 1998;  41 31-37
    Google Scholar
  • 53 Stehlin J S, Giovanella B C, Natelson E A. et al . A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer.  Int J Oncol. 1999;  14 821-831
    Google Scholar
  • 54 Safran H, Cioffi W, Iannitti D, Mega A, Akerman P. Paclitaxel and concurrent radiation for locally advanced pancreatic carcinoma.  Front Bioscience. 1998;  3 e205-e208
    Google Scholar
  • 55 Stevenson J P, Scher R M, Kosierowski R. et al . Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.  Eur J Cancer. 1998;  34 1358-1362
    Google Scholar
  • 56 Gastrointestinal tract cancer cooperative group .Studies in pancreatic cancer. URL: http://www.eortc.be/protoc/default. htm 1999
    Google Scholar
  • 57 Schmiegel W. Home-Page der AGO. URL: http://www.ruhr-uni-bochum.de/ago-dgvs/ 1999
    Google Scholar
  • 58 Latz D, Schraube P, Eble M J. Die primäre Radiotherapie des inoperablen oder rekurrenten Pankreaskarzinoms - Heidelberger Patienten von 1982 bis 1992.  Strahlenther Onkol. 1993;  169 387-393
    Google Scholar
  • 59 Gastrointestinal T umor Study Group. Radiation therapy combined with adriamycin or 5-fluoruracil for the treatment of locally unresectable cancer.  Cancer. 1985;  56 2563-2568 (Abstract)
    Google Scholar
  • 60 Gastrointestinal T umor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined modality treatment (chemotherapy plus radiotherapy) to chemotherapy alone.  J Nat Cancer Inst. 1988;  80 751-755 (Abstract)
    Google Scholar
  • 61 Moertel C G, Frytag S, Hahn R G. et al . Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluoruracil), and high doese radiation + 5-fluoruracil: The Gastrointestinal Tumor Study Group.  Cancer. 1981;  48 1705-1710 (Abstract)
    Google Scholar
  • 62 Yasue M, Sakamoto J, Kasui K. A randomized trial of intraoperative radiation therapy (IORT) vs. IORT plus cehmotherapy.  Proc Am Soc Clin Oncol. 1992;  11 161-168
    Google Scholar
  • 63 Klinkenbill J HG, Sahmoud T, van Pel R. et al . Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and peri-ampullary region: A phase III trial of the EORTC GITCCG.  Eur J Cancer. 1997;  33 274/A1239 (Abstrac) (Suppl 8)
    Google Scholar
  • 64 Warszawski N, Link K H, Lutz M P. et al . Effekt der Strahlentherapie auf das Überleben bei Patienten mit Pankreaskarzinom.  Strahlenther Onkol. 1999;  175 315-319 (Abstract)
    Google Scholar
  • 65 Nakao A, Harada A, Nonami T. et al . Intraoperative radiotherapy for pancreatic carcinoma with hepatic or peritoneal metastases.  Hepatogastroenterology. 1997;  44 1469-1471
    Google Scholar
  • 66 Pfreundner L, Baier K, Schwab F. et al . 3D-CT geplante interstitielle HDR Brachytherapie + perkutane Bestrahlung und Chemotherapie beim inoperablen Pankreaskarzinom: Methoden und Ergebnisse.  Strahlenther Onkol. 1998;  174 133-141
    Google Scholar
  • 67 Bajetta E, Di Bartolomeo M, Stani S C. et al . Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: Results of a feasibility study.  Int J Radiat Oncol Biol Phys. 1999;  45 285-289
    Google Scholar
  • 68 Hoffman J P, Lipsitz S, Pisansky T. et al . Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study.  J Clin Oncol. 1998;  16 317-323
    Google Scholar
  • 69 Heinemann V, Schermuly M M, Stieber P. et al . CA19-9: A pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.  Anticancer Res. 1999;  19 2433-2435
    Google Scholar
  • 70 van Groeningen C J. Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer.  Ann Oncol. 1999;  10 (Suppl. 4) 305-307
    Google Scholar
  • 71 Lygidakis N J, Dedemati G, Spenzaris N, Theodoropoulou M. Unresectable pancreatic cancer: Is a multi-modality a promising therapeutical alternative?.  Hepatogastroenterology. 1997;  44 1222-1228
    Google Scholar
  • 72 Beger H G, Link K H, Gansauge F. Adjuvant regional chemotherapy in advanced pancreatic cancer: Results of a prospective study.  Hepatogastroenterology. 1998;  45 638-643
    Google Scholar
  • 73 Maurer C A, Borner M M, Lauffer J. et al . Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer.  Int J Pancreatol. 1998;  23 181-186
    Google Scholar
  • 74 Aigner K R, Gailhofer S, Kopp S. Regional versus systemic chemotherapy for advanced pancreatic cancer: A randomized study.  Hepatogastroenterology. 1998;  45 1125-1129
    Google Scholar
  • 75 Müller P, Jesnowski R, Karle P. et al . Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.  Ann NY Acad Sci. 1999;  880 337-351
    Google Scholar
  • 76 Fisher W E, Muscarella P, Boros L G, Schirmer W J. Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.  Int J Pancreatol. 1998;  24 169-180
    Google Scholar
  • 77 Binmoeller K F, Seitz U, Seifert H. et al . The Tannenbaum stent: A new plastic biliary stent without side holes.  Am J Gastroenterol. 1995;  90 1764-1768
    Google Scholar
  • 78 Löhr M, Ell C. Interventionelle endoskopische Therapie des inoperablen Pankreaskarzinoms. Hopt UT, Brinkmann W Pankreaskarzinom. Neckargemünd; Weller Verlag 2000
    Google Scholar
  • 79 Klöppel G, Löhr M. Pathologische Anatomie des Pankreas. Hahn EG, Riemann JF Klinische Gastroenterologie Stuttgart; Thieme 2000 3 ed: 1097-1109
    Google Scholar
  • 80 Feretis C BP, Dimopoulos C, Manouras A, Tsimbloulis B, Apostolidis N. Duodenal obstruction caused by pancreatic head carcinoma: Palliation with self-expandable endoprostheses.  Gastrointest Endosc. 1997;  46 161-165
    Google Scholar
  • 81 Löhr M, Günzburg W H. Gentherapie des Pankreaskarzinoms.  Z Gastroenterol. 1999;  37 1201-1204
    Google Scholar
  • 82 Aspinall R J, Lemoine N R. Gene therapy for pancreatic and biliary malignancies.  Ann Oncol. 1999;  10 S188-S192 (Suppl. 4)
    Google Scholar
  • 83 Pearson A S, Bouvet M, Evans D B, Roth J A. Gene therapy and pancreatic cancer.  Front Bioscience. 1998;  3 e230-e237
    Google Scholar
  • 84 Clary B M, Lyerly H K. Gene therapy and pancreatic cancer.  Surg Clin N Am. 1998;  7 217-249
    Google Scholar
  • 85 Monia B P, Johnston J F, Geiger T, Müller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted againsted c-raf kinase.  Nat Med. 1996;  2 668-675
    Google Scholar
  • 86 Jaffee E M, Abrams R, Cameron J. et al . A phase I clinical trial of lethally irradiated allogenic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.  Hum Gene Ther. 1998;  9 1951-1971
    Google Scholar
  • 87 Gilly F N, Beaujard A, Bienvenu J. et al . Gene therapy with Adv-Il-2 in unresectable digestive cancer: Phase I-II study, intermediate report.  Hepatogastroenterology. 1999;  46 1268-1273
    Google Scholar
  • 88 Przepiorka D, Srivastava P K. Heat shock protein-peptide complexes as immunotherapy for human cancer.  Mol Med Today. 1998;  4 478-484
    Google Scholar
  • 89 Giantonio B J, Alpaugh R K, Schultz J. et al . Superantigen-based immunotherapy: A phase I trial of PNU-214 565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein in advanced pancreatic and colorectal cancer.  J Clin Oncol. 1997;  15 1994-2007
    Google Scholar
  • 90 Khleif S N, Abrams S I, Hamilton J M. et al . A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.  J Immunther. 1999;  22 155-165
    Google Scholar
  • 91 Sun J, Blaskovich M A, Knowles D. et al . Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine.  Cancer Res. 1999;  59 4919-4926
    Google Scholar
  • 92 Bramhall S R. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.  Int J Pancreatol. 1997;  21 1-12
    Google Scholar
  • 93 Jones L, Ghaneh P, Humphreys M, Neoptolemos J P. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.  Ann NY Acad Sci. 1999;  880 288-307
    Google Scholar
  • 94 Brembeck F H, Schoppmeyer K, Leupold U. et al . A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients wirth advanced pancreatic carcinoma.  Cancer. 1998;  83 2317-2323
    Google Scholar
  • 95 Moore D F, Pazdur R, Sugarman S. et al . Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma.  Am J Clin Oncol. 1995;  18 525-527
    Google Scholar
  • 96 Schmiegel W, Schmielau J, Henne-Bruns D. et al . Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer.  Proc Natl Acad Sci. 1997;  94 12 622-12 626
    Google Scholar
  • 97 Löhr M, Müller P, Karle P. et al . Targeted chemotherapy by encapsulating cells engineered to deliver CYP2B1, an ifosfamide activating cytochrome P450 gene.  Gene Ther. 1998;  5 1070-1078
    Google Scholar
  • 98 Kröger J C, Bergmeister H, Hoffmeyer A. et al . Intraarterial instillation of microencapsulated cells in the pancreatic arteries in pig.  Ann NY Acad Sci. 1999;  880 374-378
    Google Scholar
  • 99 Löhr M, Bago Z T, Bergmeister H. et al . Cell therapy using microencapsulated 293 cells transfected a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma. A phase I-study.  J Mol Med. 1999;  77 393-398
    Google Scholar
  • 100 Burris H, Stornioli A M. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluoruracil.  Eur J Cancer. 1997;  1 18-22
    Google Scholar
  • 101 Graeven U, Schmiegel W H. Therapie des Pankreaskarzinoms. Praktische Medizin - Standard und Fortschritt.  Med Klin. 1997;  92 605-606
    Google Scholar
  • 102 Carmichael J, Fink U, Russell R CG. et al . Phase II study of gemcitabine in patients with advanced pancreatic cancer.  Br J Cancer. 1996;  73 101-105
    Google Scholar
  • 103 Casper E S, Green M R, Kelsen D P. et al . Phase II trial of gemcitabine (2’,2’-di-fluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.  Invest New Drugs. 1994;  12 29-34
    Google Scholar
  • 104 Rothenberg M L, Moore M J, Cripps M C. et al . A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.  Ann Oncol. 1996;  7 347-353
    Google Scholar
  • 105 Klaassen D MJM, Catton G E, Engstrom P F, Moertel C G. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluoruracil alone with radiation plus concurrent and maintenance 5-fluoruracil.  J Clin Oncol. 1985;  3 373-378
    Google Scholar

Anschrift für die Verfasser

Prof. Dr. med. J.-Matthias Löhr

Sektion Molekulare Gastroenterologie Medizinische Klinik IV Fakultät für Klinische Medizin MannheimUniversität Heidelberg

Theodor-Kutzer-Ufer

68135 Mannheim

Fax: 06 21/3 83 19 86

Email: matthias.loehr@med4.ma.uni-heidelberg.de

      >